GNA Biosolutions completes € 6 million financing round
Prepares for market entry with fast diagnostic instruments for hospital bugs
Working with a laser-based PCR process, GNA facilitates reliable pathogen detection. The technology enables physicians and hospitals to diagnose bacterial diseases within minutes, with no need for time-consuming laboratory diagnostics. The specific DNA sequences for the pathogen under investigation are extracted and artificially multiplied (Polymerase Chain Reaction = PCR). The laser component of GNA’s technology is used for the necessary PCR thermo-cycling process (sample heating and cooling) and to read out results. Compared with traditional PCR diagnostics, this laser-based approach supplies results within just a few minutes. With low requirements in terms of sample preparation, it also facilitates the development of inexpensive diagnostics products.
GNA will use the funds from this financing round to bring its first product, the Pharos400 instrument, to market maturity. The Pharos400 processes samples with its integrated laser unit and allows a real-time detection and quantification of the results. Given its highly integrated diagnostics cartridges, Pharos400 will enable untrained hospital staff to quickly and easily obtain meaningful diagnoses. GNA will also work on developing tests for other hospital bugs. The company will focus above all on attracting university hospitals as its potential first customers.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.